Processa Pharmaceuticals, Inc. Finite-Lived Intangible Assets, Amortization Expense, Rolling Year Two
Processa Pharmaceuticals, Inc. (PCSA) had Finite-Lived Intangible Assets, Amortization Expense, Rolling Year Two of $788.50 thousand as of 2018-06-30, per its 10-Q filed 2018-08-14.
Discontinued › Notes › Goodwill and Other › Intangible Asset, Finite-Lived, and Capitalized Cost, Software to be Sold, Leased, or Marketed, Estimated Amortization Expense › Intangible Asset, Finite-Lived, after Accumulated Amortization, Rolling Maturity
us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo · last filed 2018-08-14
- 2018-06-30: Finite-Lived Intangible Assets, Amortization Expense, Rolling Year Two $788.50K.
- 2018-03-31: Finite-Lived Intangible Assets, Amortization Expense, Rolling Year Two $788.50K.
| Period end | Finite-Lived Intangible Assets, Amortization Expense, Rolling Year Two |
|---|---|
| 2018-06-30 | $788.50K 10-Q · filed 2018-08-14 |
| 2018-03-31 | $788.50K 10-Q · filed 2018-05-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |